ALX-0171 1.5 mg/kg

Phase 2Terminated

1 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Conditions

Respiratory Syncytial Virus Lower Respiratory Tract Infection

Trial Timeline

Mar 1, 2018 → Oct 24, 2018

NCT ID

NCT03418571

About ALX-0171 1.5 mg/kg

ALX-0171 1.5 mg/kg is a phase 2 stage product being developed by Sanofi for Respiratory Syncytial Virus Lower Respiratory Tract Infection. The current trial status is terminated. This product is registered under clinical trial identifier NCT03418571. Target conditions include Respiratory Syncytial Virus Lower Respiratory Tract Infection.

What happened to similar drugs?

10 of 20 similar drugs in Respiratory Syncytial Virus Lower Respiratory Tract Infection were approved

Approved (10) Terminated (3) Active (9)

✅Zopapogene imadenovec (Zopa)PrecigenApproved

✅YMC026 + PlaceboYuhanApproved

✅Montelukast + PlaceboMerckApproved

✅Sugammadex 100 MG/ML [Bridion]MerckApproved

✅diclofenac potassium + nimesulideNovartisApproved

✅Bacterial Lysates + placeboSanofiApproved

✅Telithromycin + AzithromycinSanofiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03418571	Phase 2	Terminated	Mar 1, 2018	Oct 24, 2018	Respiratory Syncytial Virus Lower Respiratory Tract Infection

Competing Products

20 competing products in Respiratory Syncytial Virus Lower Respiratory Tract Infection

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 2	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Preclinical	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 3	0
mRNA-1345	Moderna	Phase 1	0
Zopapogene imadenovec (Zopa)	Precigen	Approved	44
PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2	Precigen	Phase 1/2	30
agenT-797	MiNK Therapeutics	Phase 1	19
YMC026 + Placebo	Yuhan	Approved	43
VN-0200 + Placebo	Daiichi Sankyo	Phase 1	29
VN-0200	Daiichi Sankyo	Phase 2	35
Isavuconazonium Injection [Cresemba] + Placebo	Astellas Pharma	Phase 3	32
S-337395 + Placebo	Shionogi	Phase 2	42
Sivelestat	Eli Lilly	Phase 1/2	32